Search

Search Results

1. Lifetime risks of second primary malignancies after pediatric Hodgkin lymphoma and non-Hodgkin lymphoma

   Objectives

   Survivors after pediatric Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL) are with lifetime risk for second primary malignancy...

   Laduona Wang, Yue Zheng, ... Yijun Wu in Journal of Cancer Research and Clinical Oncology

   Article Open access 27 January 2024
   

2. Unusual Presentation of Non-Hodgkin Lymphoma of Two Cases: Case Report

   Lymphomas are a diverse group of neoplastic disorders arising primarily in lymph nodes. They have been majorly classified into Hodgkin and...

   Haritha S, Shyam Sudhakar Sudarsan, ... Sakthimurugan Sankar in Indian Journal of Otolaryngology and Head & Neck Surgery

   Article 26 April 2024
   

3. Comparison of diffusion-weighted MRI and [¹⁸F]FDG PET/MRI for treatment monitoring in pediatric Hodgkin and non-Hodgkin lymphoma

   Objective

   To compare tumor therapy response assessments with whole-body diffusion-weighted imaging (WB-DWI) and 18F-fluorodeoxyglucose ([ ¹⁸ F]FDG)...

   Wipawee Morakote, Lucia Baratto, ... Heike E. Daldrup-Link in European Radiology

   Article 05 August 2023
   

4. Efficacy and safety of lenalidomide in the treatment of B-cell non-Hodgkin lymphoma

   Background

   The combination of rituximab and chemotherapy is a first-line treatment for patients with B-cell non-Hodgkin lymphoma. Lenalidomide is an...

   Yang Liu, Yanju Li, ... Feiqing Wang in Discover Oncology

   Article Open access 05 April 2024
   

5. Prognostic significance of serum monoclonal proteins based on immunofixation electrophoresis in B-cell non-Hodgkin lymphoma

   The presence of serum monoclonal components has been associated with poor outcomes in various hematological malignancies. The current study focused...

   Yuyang Gao, **aoyan Feng, ... Mingzhi Zhang in Annals of Hematology

   Article 20 December 2023
   

6. Epiregulin: A new prognostic molecule in non-Hodgkin lymphoma

   Background

   Epiregulin is a molecule that plays a role in cell proliferation, tumor development, inflammation, and angiogenesis in malignant diseases.

   ...

   Ismail Demir, Ozden Yildirim Akan, ... Oktay Bilgir in Irish Journal of Medical Science (1971 -)

   Article 25 January 2024
   

7. Exposure–response analysis of Camidanlumab tesirine in patients with relapsed or refractory classical Hodgkin lymphoma and non-Hodgkin lymphoma

   Purpose

   To investigate camidanlumab tesirine (Cami) exposure–response (E–R) relationships, using an integrated population pharmacokinetic model, for...

   Marie Toukam, Joseph P. Boni, ... Jens Wuerthner in Cancer Chemotherapy and Pharmacology

   Article 04 November 2022
   

8. In silico study of polyphenols as potential inhibitors of MALT1 protein in non-Hodgkin lymphoma

   Non-Hodgkin lymphoma (NHL) is one of the most common cancer types. Deregulated signaling pathways can trigger certain NHL subtypes, including Diffuse...

   Abas Sezer, Lejla Mahmutović, Betül Akçeşme in Medical Oncology

   Article 28 December 2023
   

9. Survival trend and outcome prediction for pediatric Hodgkin and non-Hodgkin lymphomas based on machine learning

   Pediatric Hodgkin and non-Hodgkin lymphomas differ from adult cases in biology and management, yet there is a lack of survival analysis tailored to...

   Yue Zheng, Chunlan Zhang, ... Yijun Wu in Clinical and Experimental Medicine

   Article Open access 18 June 2024
   

10. Second primary malignancies in non-Hodgkin lymphoma: epidemiology and risk factors

    With the advancements in therapeutics for non-Hodgkin lymphoma (NHL), the long-term survival of patients with NHL has markedly increased. Second...

    Zhumei Zhan, Wei Guo, ... Ou Bai in Annals of Hematology

    Article 09 January 2023
    

11. Distinct germline genetic susceptibility profiles identified for common non-Hodgkin lymphoma subtypes

    Lymphoma risk is elevated for relatives with common non-Hodgkin lymphoma (NHL) subtypes, suggesting shared genetic susceptibility across subtypes. To...

    Sonja I. Berndt, Joseph Vijai, ... Nathaniel Rothman in Leukemia

    Article 22 October 2022
    

12. Correlation between the Human Development Index and the Incidence and Mortality of Non-Hodgkin Lymphoma

    Objective

    This study was to examine the relationship between socioeconomic status and the incidence and mortality of non-Hodgkin lymphoma (NHL).

    ...

    Wen-fu Xu, ** Yang, ... Zhu-jun Wang in Current Medical Science

    Article 21 March 2023

13. Allogeneic stem cell transplantation and CAR-T in B-cell Non-Hodgkin Lymphoma: a two-center experience and review of the literature

    Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is still a potentially curative option for B-cell Non-Hodgkin Lymphoma (B-NHL) in the...

    Santiago Mercadal, Alberto Mussetti, ... Daniel R. Couriel in Annals of Hematology

    Article 02 March 2024
    

14. Non-Hodgkin lymphoma mimicking acute leukemia: a report of six cases and review of the literature

    Aggressive subtypes of non-Hodgkin lymphoma may uncommonly be referred to clinical oncologists for treatment of acute leukemia, due to an elevated or...

    David M. Dorfman, Sam Sadigh in Journal of Hematopathology

    Article 23 April 2022
    

15. Population pharmacokinetics analysis of camidanlumab tesirine in patients with relapsed or refractory Hodgkin lymphoma and non-Hodgkin lymphoma

    Purpose

    The objective of this analysis was to develop a population pharmacokinetic (PPK) model to characterize camidanlumab tesirine (Cami)...

    Marie Toukam, Jens Wuerthner, ... Joseph P. Boni in Cancer Chemotherapy and Pharmacology

    Article 04 November 2022
    

16. Trends in physical functioning in acute lymphoblastic leukemia and non-Hodgkin lymphoma survivors across three decades

    Purpose

    The impact of changes in therapy for childhood acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma (NHL) on the prevalence of physical...

    Carmen L. Wilson, Kari L. Bjornard, ... Kirsten K. Ness in Journal of Cancer Survivorship

    Article 08 November 2023
    

17. The association of body composition and outcomes following autologous hematopoietic stem cell transplantation in patients with non-Hodgkin lymphoma

    Recently there has been a growing interest in evaluating body composition as a marker for prognosis in cancer patients. The association of body...

    Gabriel F. P. Aleixo, Wei Wei, ... Navneet S. Majhail in Bone Marrow Transplantation

    Article 12 September 2023
    

18. An extremely rare presentation of non-Hodgkin lymphoma in the head and neck: a case report

    Background

    Non-Hodgkin lymphoma (NHL) frequently presents as extra-nodal involvement, although primary diffuse large B cell lymphoma of extra-nodal...

    Sevil Nasirmohtaram, Alireza Mesbah, Farnaz Mazloom in The Egyptian Journal of Otolaryngology

    Article Open access 29 August 2022
    

19. Anti-CD20 antibodies and bendamustine attenuate humoral immunity to COVID-19 vaccination in patients with B-cell non-Hodgkin lymphoma

    Serologic responses of COVID-19 vaccine are impaired in patients with B-cell lymphoma, especially those who had recently been treated with anti-CD20...

    Takashi Ishio, Shihori Tsukamoto, ... Takeshi Kondo in Annals of Hematology

    Article Open access 12 April 2023
    

20. Clinical features and prognosis of double primary malignant neoplasms in patients with non-hodgkin lymphoma

    To investigate the clinical features, survival, and prognostic factors of patients with double primary malignant neoplasms (DPMNs) comprising...

    Zhumei Zhan, Wei Guo, ... Ou Bai in Discover Oncology

    Article Open access 03 May 2023